Image-Guided Drug Delivery Market - A Global and Regional Analysis: Focus on Technology Type, Application, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
This report can be delivered within 1 working day.
Introduction of Image-Guided Drug Delivery
Image-Guided Drug Delivery applies advanced, precision-driven, minimally invasive techniques to deliver therapeutics directly to targeted disease sites, including tumors and neurological regions. This innovative field represents a paradigm shift in modern medicine, moving beyond conventional systemic therapies toward safer, more localized, and patient-specific interventions. By combining specialized drug delivery systems such as catheters and cannulae with MRI, CT, and ultrasound-based imaging platforms, augmented by robotics and AI-driven navigation, image-guided drug delivery enables clinicians to administer gene therapies, chemotherapeutics, and cell-based treatments with exceptional accuracy and control. This approach improves therapeutic efficacy, minimizes systemic toxicity, shortens recovery times, and optimizes healthcare resources, positioning image-guided drug delivery as a cornerstone of next-generation precision medicine.
Market Introduction
The global image-guided drug delivery market is expected to witness significant growth, projected to reach $983.0 million by 2035, driven by the escalating global burden of cancer, neurological disorders, and other chronic diseases that demand safer, more precise, and less invasive therapeutic approaches. Anchored in catheter-based infusion systems, multiport cannulae, and image-guided navigation platforms, IGDD integrates advanced imaging, robotics, and AI to deliver localized therapies with superior accuracy, minimized systemic toxicity, and improved patient outcomes.
Image-guided drug delivery represents a paradigm shift in modern medicine, combining imaging precision, controlled infusion, and real-time monitoring to expand access to targeted therapies. Key milestones, such as the FDA De Novo clearance of ClearPoint Neuro’s SmartFlow Cannula, the first U.S.-approved device for intracerebral gene therapy—and the commercial launch of TriSalus Life Sciences’ TriNav FLX infusion system, have validated these disruptive approaches. Similarly, software-driven navigation platforms such as Koninklijke Philips’ EmboGuide and GE HealthCare’s FlightPlan for Liver underscore the move toward standardization and reproducibility in complex oncology and neurology procedures.
Market expansion is further supported by favorable regulatory and reimbursement frameworks in North America, Europe, and Japan, coupled with increasing investments from the public and private sectors in hybrid operating suites, imaging infrastructure, and training for interventional specialists. Countries across North America, Europe, and Asia-Pacific are scaling hospital capacity and fostering innovation hubs, while emerging markets such as India, Brazil, and Southeast Asia present untapped potential for growth as precision medicine adoption accelerates.
Technological convergence is a key accelerator, with innovations in AI-assisted infusion planning, MRI-compatible surgical robotics, and multimodal imaging enhancing both delivery accuracy and long-term therapeutic outcomes. While oncology remains the dominant application, neurology is rapidly expanding, particularly in gene and cell therapy delivery for conditions such as glioblastoma, Parkinson’s disease, and AADC deficiency. Broader applications in gastrointestinal and cardiovascular disorders are also beginning to extend the scope of image-guided drug delivery technologies.
Despite strong momentum, challenges such as high acquisition costs, workflow integration barriers, and uneven access in low- and middle-income regions remain. However, growing payer support, coupled with industry–academic–biopharma collaborations, is steadily overcoming these hurdles by accelerating clinical validation and lowering barriers to adoption.
Leading players such as ClearPoint Neuro, Inc., TriSalus Life Sciences, Inc., RenovoRx, Koninklijke Philips N.V., GE HealthCare, and AiM Medical Robotics are shaping the competitive landscape, advancing first-in-class devices, building robust clinical evidence, and pursuing commercialization strategies across oncology and neurology. As healthcare increasingly emphasizes precision medicine, minimally invasive delivery, and patient-centric care, image-guided drug delivery is positioned at the forefront of therapeutic innovation, set to redefine treatment paradigms and improve outcomes for patients worldwide.
Industrial Impact
Image-guided drug delivery is reshaping therapeutic care in oncology and neurology by enabling minimally invasive, precision-guided administration of advanced treatments. Catheter-based infusion platforms such as ClearPoint Neuro’s SmartFlow Cannula and TriSalus Life Sciences’ TriNav FLX have redefined procedural accuracy, allowing direct drug and gene therapy delivery into targeted brain regions or solid tumors. By overcoming barriers such as the blood–brain barrier and ensuring localized drug penetration, IGDD technologies are improving efficacy, reducing systemic toxicity, and minimizing hospital stays—positioning them as critical enablers of next-generation personalized medicine.
Beyond individual procedures, image-guided drug delivery is fostering innovation across procedural ecosystems and clinical workflows. Integration of MRI/CT-guided navigation platforms ,robotic systems, and AI-assisted infusion planning tools is standardizing drug placement, enabling real-time therapy monitoring, and expanding treatment options for hard-to-reach tumors and CNS disorders. These platforms streamline clinical decision-making, reduce procedural variability, and make therapies more reproducible across institutions.
Simultaneously, strategic collaborations between device innovators, pharmaceutical companies, and academic research centers are accelerating the adoption of image-guided drug delivery in cell and gene therapy trials, with >60 biopharma partners already leveraging ClearPoint Neuro’s systems for CNS-targeted delivery. Supportive regulatory pathways, such as the FDA’s De Novo clearance of SmartFlow and EU MDR certifications, coupled with increasing reimbursement for precision infusion procedures, are driving commercial momentum.
At a system-wide level, Image-guided drug delivery is enhancing healthcare resilience by broadening access to advanced therapies, particularly in tertiary-care hospitals and cancer centers. Investments in hybrid ORs, neuro-interventional suites, and digital imaging infrastructure are enabling scalability of these technologies, while partnerships with global leaders such as Koninklijke Philips N.V., GE HealthCare, and innovative biotech firms are pushing IGDD toward mainstream adoption. Collectively, these advancements are redefining treatment delivery, improving patient outcomes, and strengthening the foundations of precision therapy in oncology and neurology.
Market Segmentation:
Segmentation 1: By Technology Type
In contrast, Image-Guided Platforms including ClearPoint Navigation, Philips EmboGuide, and GE FlightPlan for Liver are growing rapidly as they improve feeder-vessel detection, enhance targeting accuracy, and standardize procedures. While smaller today, IGPs are expected to capture increasing share as clinical workflows demand greater imaging integration.
Segmentation 2: By Application
Segmentation 3: By End User
Segmentation 4: By Region
Recent Developments in the Image-Guided Drug Delivery Market
Market Demand Drivers:
By minimizing off-target effects, this technique significantly enhances therapeutic outcomes. Moreover, the ability to adjust treatment in real-time optimizes drug delivery, ensuring that the right dosage reaches the right location. This precision is especially impactful in areas such as prostate cancer and neurodegenerative diseases, where accurate drug targeting can markedly improve patient outcomes.Some of the other driving factors include:
Market Restraints:
As a result, this financial barrier not only limits the adoption of image-guided drug delivery systems in clinical environments but also hinders the overall expansion of the market. Smaller healthcare providers in emerging economies, where budgets are stretched thin, often cannot afford to invest in such technology, which may be perceived as non-essential in comparison to other immediate healthcare needs. This leads to a concentration of image-guided drug delivery technology in a small number of well-funded hospitals, restricting its broader application and diminishing its potential impact on patient care in underserved regions. Consequently, patients in these areas miss out on the benefits of more precise, targeted drug delivery, which is particularly valuable in cancer treatment and other specialized medical procedures requiring high levels of accuracy.
Market Opportunities:
Market Trends:
Integration of Imaging with Targeted Drug Delivery
The integration of imaging with targeted drug delivery is a pivotal trend in modern medicine, fundamentally reshaping therapeutic approaches in both neurology and oncology. This paradigm shift is driven by a convergence of key developments, including significant regulatory milestones, growing clinical adoption, the launch of innovative new devices, and robust market momentum. This convergence is profoundly impacting the image-guided drug delivery market, transforming it from a niche, research-focused field into a rapidly expanding sector for mainstream clinical applications. This shift is fueled by the FDA's De Novo clearance of devices such as ClearPoint Neuro’s SmartFlow Neuro Cannula, which validates a clear regulatory pathway for similar technologies, thereby reducing risk for investors and accelerating commercialization. On a clinical level, the use of real-time imaging and specialized catheters allows for unprecedented precision, ensuring a higher concentration of the therapeutic agent reaches the target site while sparing healthy tissue.
This not only improves treatment efficacy and reduces toxicity but also creates standardized, repeatable workflows that are more efficient and cost-effective for hospitals. The market is seeing a surge of new, purpose-built devices such as RenovoRx’s RenovoCath and TriSalus Life Sciences’ TriNav FLX, which are driving high-growth segments in targeted oncology and CNS delivery. Ultimately, the convergence of specialized delivery devices and image-guided navigation is creating a new standard of care, leading to reduced complications, higher procedure volumes, and improved patient outcomes in these critical therapeutic areas.
How can this report add value to an organization?
Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in Image-Guided Drug Delivery, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.
Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.
Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors’ strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.
Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Image-Guided Drug Delivery
Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
The primary sources involve industry experts in Image-Guided Drug Delivery, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Open Sources
Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.
Key players in the image-guided drug delivery market include global medical device and imaging companies offering a broad range of drug delivery systems and image-guided platforms for oncology and neurology. Established firms such as ClearPoint Neuro, Inc., Koninklijke Philips N.V., and GE HealthCare dominate with portfolios spanning MRI-guided navigation, infusion cannulae, and vessel-mapping software integrated into interventional oncology and CNS therapies.
Innovators are developing multiport catheters, pressure-enabled infusion systems, and AI-assisted navigation software to improve delivery accuracy and therapeutic outcomes. Companies like TriSalus Life Sciences and RenovoRx are pioneering catheter-based oncology platforms, while AiM Medical Robotics and others are advancing MRI-compatible surgical robots for neurosurgical delivery. Emerging players, including Neurochase and Infuseon Therapeutics, are introducing novel convection-enhanced delivery systems for direct brain infusion.
Start-ups and regional firms are also contributing with cost-effective infusion technologies, portable navigation tools, and specialized drug-device combinations targeting unmet needs in emerging markets. Collectively, these companies are driving innovation, expanding clinical access, and establishing image-guided drug delivery as a cornerstone of precision-guided, minimally invasive therapeutic delivery.
Some prominent names established in this market are:
Introduction of Image-Guided Drug Delivery
Image-Guided Drug Delivery applies advanced, precision-driven, minimally invasive techniques to deliver therapeutics directly to targeted disease sites, including tumors and neurological regions. This innovative field represents a paradigm shift in modern medicine, moving beyond conventional systemic therapies toward safer, more localized, and patient-specific interventions. By combining specialized drug delivery systems such as catheters and cannulae with MRI, CT, and ultrasound-based imaging platforms, augmented by robotics and AI-driven navigation, image-guided drug delivery enables clinicians to administer gene therapies, chemotherapeutics, and cell-based treatments with exceptional accuracy and control. This approach improves therapeutic efficacy, minimizes systemic toxicity, shortens recovery times, and optimizes healthcare resources, positioning image-guided drug delivery as a cornerstone of next-generation precision medicine.
Market Introduction
The global image-guided drug delivery market is expected to witness significant growth, projected to reach $983.0 million by 2035, driven by the escalating global burden of cancer, neurological disorders, and other chronic diseases that demand safer, more precise, and less invasive therapeutic approaches. Anchored in catheter-based infusion systems, multiport cannulae, and image-guided navigation platforms, IGDD integrates advanced imaging, robotics, and AI to deliver localized therapies with superior accuracy, minimized systemic toxicity, and improved patient outcomes.
Image-guided drug delivery represents a paradigm shift in modern medicine, combining imaging precision, controlled infusion, and real-time monitoring to expand access to targeted therapies. Key milestones, such as the FDA De Novo clearance of ClearPoint Neuro’s SmartFlow Cannula, the first U.S.-approved device for intracerebral gene therapy—and the commercial launch of TriSalus Life Sciences’ TriNav FLX infusion system, have validated these disruptive approaches. Similarly, software-driven navigation platforms such as Koninklijke Philips’ EmboGuide and GE HealthCare’s FlightPlan for Liver underscore the move toward standardization and reproducibility in complex oncology and neurology procedures.
Market expansion is further supported by favorable regulatory and reimbursement frameworks in North America, Europe, and Japan, coupled with increasing investments from the public and private sectors in hybrid operating suites, imaging infrastructure, and training for interventional specialists. Countries across North America, Europe, and Asia-Pacific are scaling hospital capacity and fostering innovation hubs, while emerging markets such as India, Brazil, and Southeast Asia present untapped potential for growth as precision medicine adoption accelerates.
Technological convergence is a key accelerator, with innovations in AI-assisted infusion planning, MRI-compatible surgical robotics, and multimodal imaging enhancing both delivery accuracy and long-term therapeutic outcomes. While oncology remains the dominant application, neurology is rapidly expanding, particularly in gene and cell therapy delivery for conditions such as glioblastoma, Parkinson’s disease, and AADC deficiency. Broader applications in gastrointestinal and cardiovascular disorders are also beginning to extend the scope of image-guided drug delivery technologies.
Despite strong momentum, challenges such as high acquisition costs, workflow integration barriers, and uneven access in low- and middle-income regions remain. However, growing payer support, coupled with industry–academic–biopharma collaborations, is steadily overcoming these hurdles by accelerating clinical validation and lowering barriers to adoption.
Leading players such as ClearPoint Neuro, Inc., TriSalus Life Sciences, Inc., RenovoRx, Koninklijke Philips N.V., GE HealthCare, and AiM Medical Robotics are shaping the competitive landscape, advancing first-in-class devices, building robust clinical evidence, and pursuing commercialization strategies across oncology and neurology. As healthcare increasingly emphasizes precision medicine, minimally invasive delivery, and patient-centric care, image-guided drug delivery is positioned at the forefront of therapeutic innovation, set to redefine treatment paradigms and improve outcomes for patients worldwide.
Industrial Impact
Image-guided drug delivery is reshaping therapeutic care in oncology and neurology by enabling minimally invasive, precision-guided administration of advanced treatments. Catheter-based infusion platforms such as ClearPoint Neuro’s SmartFlow Cannula and TriSalus Life Sciences’ TriNav FLX have redefined procedural accuracy, allowing direct drug and gene therapy delivery into targeted brain regions or solid tumors. By overcoming barriers such as the blood–brain barrier and ensuring localized drug penetration, IGDD technologies are improving efficacy, reducing systemic toxicity, and minimizing hospital stays—positioning them as critical enablers of next-generation personalized medicine.
Beyond individual procedures, image-guided drug delivery is fostering innovation across procedural ecosystems and clinical workflows. Integration of MRI/CT-guided navigation platforms ,robotic systems, and AI-assisted infusion planning tools is standardizing drug placement, enabling real-time therapy monitoring, and expanding treatment options for hard-to-reach tumors and CNS disorders. These platforms streamline clinical decision-making, reduce procedural variability, and make therapies more reproducible across institutions.
Simultaneously, strategic collaborations between device innovators, pharmaceutical companies, and academic research centers are accelerating the adoption of image-guided drug delivery in cell and gene therapy trials, with >60 biopharma partners already leveraging ClearPoint Neuro’s systems for CNS-targeted delivery. Supportive regulatory pathways, such as the FDA’s De Novo clearance of SmartFlow and EU MDR certifications, coupled with increasing reimbursement for precision infusion procedures, are driving commercial momentum.
At a system-wide level, Image-guided drug delivery is enhancing healthcare resilience by broadening access to advanced therapies, particularly in tertiary-care hospitals and cancer centers. Investments in hybrid ORs, neuro-interventional suites, and digital imaging infrastructure are enabling scalability of these technologies, while partnerships with global leaders such as Koninklijke Philips N.V., GE HealthCare, and innovative biotech firms are pushing IGDD toward mainstream adoption. Collectively, these advancements are redefining treatment delivery, improving patient outcomes, and strengthening the foundations of precision therapy in oncology and neurology.
Market Segmentation:
Segmentation 1: By Technology Type
- Drug-Delivery Systems
- Image-Guided Platforms
In contrast, Image-Guided Platforms including ClearPoint Navigation, Philips EmboGuide, and GE FlightPlan for Liver are growing rapidly as they improve feeder-vessel detection, enhance targeting accuracy, and standardize procedures. While smaller today, IGPs are expected to capture increasing share as clinical workflows demand greater imaging integration.
Segmentation 2: By Application
- Oncology
- Neurology
- Others
Segmentation 3: By End User
- Hospitals
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Research Institutes & Universities
Segmentation 4: By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
- Asia-Pacific
- Japan
- India
- China
- Australia
- South Korea
- Rest-of-Asia-Pacific
- Rest-of-the-World
Recent Developments in the Image-Guided Drug Delivery Market
- In August 2025, ClearPoint Neuro, Inc. reported the first-ever commercial delivery of KEBILIDI (AADC deficiency gene therapy) in the U.S. using its FDA-authorized SmartFlow Neuro Cannula, marking a pivotal step in clinical implementation.
- In June 2025, TriSalus Life Sciences, Inc. rolled out the TriNavFLX Infusion System, a new addition to its Pressure Enabled Drug Delivery (PEDD) line. The system's distal end is twice as long and more flexible than previous models, enabling smooth navigation through tortuous vessels. In benchtop testing, it reduced navigation force by 28% compared to the standard TriNav.
- In May 2025, ClearPoint Neuro, Inc. entered into a structured financing agreement with Oberland Capital for up to $110 million, including note financing and equity components.
- In April 2025, Johns Hopkins Medicine joined RenovoRx’s TIGeR-PaC trial, enrolling patients with locally advanced pancreatic cancer (LAPC). The trial evaluates RenovoRx's intra-arterial gemcitabine (IAG) delivery via the RenovoCath device, comparing it to standard intravenous chemotherapy. This addition strengthens the trial, aiming for full enrollment by 2025.
- In April 2025, ClearPoint Neuro, Inc. released ClearPoint Navigation Software Version 3.0, the first full end-to-end ClearPoint navigation solution specifically designed for standard operating rooms. It introduces a new iCT-guided workflow, enabling high-precision brain navigation without requiring MRI infrastructure.
Market Demand Drivers:
- Increased Demand for Personalized Medicine
By minimizing off-target effects, this technique significantly enhances therapeutic outcomes. Moreover, the ability to adjust treatment in real-time optimizes drug delivery, ensuring that the right dosage reaches the right location. This precision is especially impactful in areas such as prostate cancer and neurodegenerative diseases, where accurate drug targeting can markedly improve patient outcomes.Some of the other driving factors include:
- Rising Prevalence of Chronic Diseases
Market Restraints:
- High Acquisition Cost of the Instruments
As a result, this financial barrier not only limits the adoption of image-guided drug delivery systems in clinical environments but also hinders the overall expansion of the market. Smaller healthcare providers in emerging economies, where budgets are stretched thin, often cannot afford to invest in such technology, which may be perceived as non-essential in comparison to other immediate healthcare needs. This leads to a concentration of image-guided drug delivery technology in a small number of well-funded hospitals, restricting its broader application and diminishing its potential impact on patient care in underserved regions. Consequently, patients in these areas miss out on the benefits of more precise, targeted drug delivery, which is particularly valuable in cancer treatment and other specialized medical procedures requiring high levels of accuracy.
Market Opportunities:
- Integration of Artificial Intelligence in Image-Guided Drug Delivery
Market Trends:
Integration of Imaging with Targeted Drug Delivery
The integration of imaging with targeted drug delivery is a pivotal trend in modern medicine, fundamentally reshaping therapeutic approaches in both neurology and oncology. This paradigm shift is driven by a convergence of key developments, including significant regulatory milestones, growing clinical adoption, the launch of innovative new devices, and robust market momentum. This convergence is profoundly impacting the image-guided drug delivery market, transforming it from a niche, research-focused field into a rapidly expanding sector for mainstream clinical applications. This shift is fueled by the FDA's De Novo clearance of devices such as ClearPoint Neuro’s SmartFlow Neuro Cannula, which validates a clear regulatory pathway for similar technologies, thereby reducing risk for investors and accelerating commercialization. On a clinical level, the use of real-time imaging and specialized catheters allows for unprecedented precision, ensuring a higher concentration of the therapeutic agent reaches the target site while sparing healthy tissue.
This not only improves treatment efficacy and reduces toxicity but also creates standardized, repeatable workflows that are more efficient and cost-effective for hospitals. The market is seeing a surge of new, purpose-built devices such as RenovoRx’s RenovoCath and TriSalus Life Sciences’ TriNav FLX, which are driving high-growth segments in targeted oncology and CNS delivery. Ultimately, the convergence of specialized delivery devices and image-guided navigation is creating a new standard of care, leading to reduced complications, higher procedure volumes, and improved patient outcomes in these critical therapeutic areas.
How can this report add value to an organization?
Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in Image-Guided Drug Delivery, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.
Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.
Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors’ strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.
Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Image-Guided Drug Delivery
Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
- The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2023. The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
- The scope of this report has been carefully derived based on extensive interactions with experts and stakeholders across leading companies and research institutions worldwide. This report provides a comprehensive market analysis of robotics and non-robotics within the Image-Guided Drug Delivery market.
- Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
- The market has been mapped based on the available Image-Guided Drug Delivery products. All the key companies with significant offerings in this field have been considered and profiled in this report.
The primary sources involve industry experts in Image-Guided Drug Delivery, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
- Validation and triangulation of all the numbers and graphs
- Validation of the report’s segmentation and key qualitative findings
- Understanding the competitive landscape and business model
- Current and proposed production values of a product by market players
- Validation of the numbers of the different segments of the market in focus
- Percentage split of individual markets for regional analysis
Open Sources
- Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
- Annual reports, SEC filings, and investor presentations of the leading market players
- Company websites and detailed study of their product portfolio
- Gold standard magazines, journals, white papers, press releases, and news articles
- Paid databases
- Segmentations and percentage shares
- Data for market value
- Key industry trends of the top players of the market
- Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
- Quantitative data for mathematical and statistical calculations
Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.
Key players in the image-guided drug delivery market include global medical device and imaging companies offering a broad range of drug delivery systems and image-guided platforms for oncology and neurology. Established firms such as ClearPoint Neuro, Inc., Koninklijke Philips N.V., and GE HealthCare dominate with portfolios spanning MRI-guided navigation, infusion cannulae, and vessel-mapping software integrated into interventional oncology and CNS therapies.
Innovators are developing multiport catheters, pressure-enabled infusion systems, and AI-assisted navigation software to improve delivery accuracy and therapeutic outcomes. Companies like TriSalus Life Sciences and RenovoRx are pioneering catheter-based oncology platforms, while AiM Medical Robotics and others are advancing MRI-compatible surgical robots for neurosurgical delivery. Emerging players, including Neurochase and Infuseon Therapeutics, are introducing novel convection-enhanced delivery systems for direct brain infusion.
Start-ups and regional firms are also contributing with cost-effective infusion technologies, portable navigation tools, and specialized drug-device combinations targeting unmet needs in emerging markets. Collectively, these companies are driving innovation, expanding clinical access, and establishing image-guided drug delivery as a cornerstone of precision-guided, minimally invasive therapeutic delivery.
Some prominent names established in this market are:
- ClearPoint Neuro, Inc.
- TriSalus Life Sciences, Inc.
- GE Healthcare
- Koninklijke Philips N.V.
- RenovoRx Inc.
Executive Summary
Scope and Definition
1 MARKET: INDUSTRY OUTLOOK
1.1 Competitive Landscape
1.2 Industry Outlook
1.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
1.2.2 Market Trends
1.2.2.1 Integration of Imaging with Targeted Drug Delivery
1.2.3 Advancements in Image-Guided Drug Delivery
1.2.4 Future Direction and Emerging Technologies in Image-Guided Drug Delivery
1.3 Market Dynamics
1.3.1 Impact Analysis
1.3.2 Market Driver
1.3.2.1 Increased Demand for Personalized Medicine
1.3.2.2 Rising Prevalence of Chronic Diseases
1.3.2.3 Technological Advancements in Image-Guided Drug Delivery
1.3.3 Market Restraint
1.3.3.1 High Acquisition Cost of the Instruments
1.3.4 Market Opportunity
1.3.4.1 Integration of Artificial Intelligence in Image-Guided Drug Delivery
2 TECHNOLOGY
2.1 Overview
2.2 Drug Delivery Systems
2.3 Image-Guided Platforms
3 APPLICATION
3.1 Overview
3.2 Oncology
3.3 Neurology
3.4 Others
4 END USER
4.1 Overview
4.2 Hospitals
4.3 Research Institutes and Universities
4.4 Pharmaceutical and Biotechnology Companies
4.5 Contract Research Organizations (CROs)
5 REGION
5.1 Regional Summary
5.2 North America
5.2.1 Regional Overview
5.2.2 Driving Factors for Market Growth
5.2.3 Factors Challenging the Market
5.2.4 By Technology Type
5.2.5 By Application
5.2.6 By End User
5.2.7 By Country
5.2.7.1 U.S.
5.2.8 By Technology Type
5.2.9 By Application
5.2.10 By End User
5.2.10.1 Canada
5.2.11 By Technology Type
5.2.12 By Application
5.2.13 By End User
5.3 Europe
5.3.1 Regional Overview
5.3.2 Driving Factors for Market Growth
5.3.3 Factors Challenging the Market
5.3.4 By Technology Type
5.3.5 By Application
5.3.6 By End User
5.3.7 By Country
5.3.7.1 U.K.
5.3.8 By Technology Type
5.3.9 By Application
5.3.10 By End User
5.3.10.1 Germany
5.3.11 By Technology Type
5.3.12 By Application
5.3.13 By End User
5.3.13.1 France
5.3.14 By Technology Type
5.3.15 By Application
5.3.16 By End User
5.3.16.1 Italy
5.3.17 By Technology Type
5.3.18 By Application
5.3.19 By End User
5.3.19.1 Spain
5.3.20 By Technology Type
5.3.21 By Application
5.3.22 By End User
5.3.22.1 Rest-of-Europe
5.3.23 By Technology Type
5.3.24 By Application
5.3.25 By End User
5.4 Asia-Pacific
5.4.1 Regional Overview
5.4.2 Driving Factors for Market Growth
5.4.3 Factors Challenging the Market
5.4.4 By Technology Type
5.4.5 By Application
5.4.6 By End User
5.4.7 By Country
5.4.7.1 Japan
5.4.8 By Technology Type
5.4.9 By Application
5.4.10 By End User
5.4.10.1 China
5.4.11 By Technology Type
5.4.12 By Application
5.4.13 By End User
5.4.13.1 India
5.4.14 By Technology Type
5.4.15 By Application
5.4.16 By End User
5.4.16.1 Australia
5.4.17 By Technology Type
5.4.18 By Application
5.4.19 By End User
5.4.19.1 South Korea
5.4.20 By Technology Type
5.4.21 By Application
5.4.22 By End User
5.4.22.1 Rest-of-Asia-Pacific
5.4.23 By Technology Type
5.4.24 By Application
5.4.25 By End User
5.5 Rest-of-the-World
5.5.1 Regional Overview
5.5.2 Driving Factors for Market Growth
5.5.3 Factors Challenging the Market
5.5.4 By Technology Type
5.5.5 By Application
5.5.6 By End User
5.5.7 Latin America
5.5.7.1 Regional Overview
5.5.7.2 Driving Factors for Market Growth
5.5.7.3 Factors Challenging the Market
5.5.8 Middle East and Africa
5.5.8.1 Regional Overview
5.5.8.2 Driving Factors for Market Growth
5.5.8.3 Factors Challenging the Market
5.5.9 Rest-of-the-World Country Overview
6 MARKETS - COMPANY PROFILES
6.1 Company Profiles
6.1.1 ClearPoint Neuro, Inc.
6.1.1.1 Overview
6.1.1.2 Top Products/Product Portfolio
6.1.1.3 Top Competitors
6.1.1.4 Target Customers
6.1.1.5 Key Personnel
6.1.1.6 Analyst View
6.1.1.7 ClearPoint Neuro, Inc., Revenue ($Thousand), 2022-2024
6.1.2 AiM Medical Robotics
6.1.2.1 Overview
6.1.2.2 Pipeline Product Portfolio
6.1.2.3 Top Competitors
6.1.2.4 Target Customers
6.1.2.5 Key Personnel
6.1.2.6 Analyst View
6.1.3 TriSalus Life Sciences
6.1.3.1 Overview
6.1.3.2 Top Products/Product Portfolio
6.1.3.3 Top Competitors
6.1.3.4 Target Customers
6.1.3.5 Key Personnel
6.1.3.6 Analyst View
6.1.3.7 TriSalus Life Sciences, Revenue ($Thousand), 2022-2024
6.1.4 RenovoRx Inc.
6.1.4.1 Overview
6.1.4.2 Top Products/Product Portfolio
6.1.4.3 Top Competitors
6.1.4.4 Target Customers
6.1.4.5 Key Personnel
6.1.4.6 Analyst View
6.1.4.7 RenovoRx Inc., Revenue ($Thousand), 2022-2024
6.1.5 Renishaw plc.
6.1.5.1 Overview
6.1.5.2 Pipeline Product Portfolio
6.1.5.3 Top Competitors
6.1.5.4 Target Customers
6.1.5.5 Key Personnel
6.1.5.6 Analyst View
6.1.5.7 Renishaw plc., Revenue ($Million), 2022-2024
6.1.6 Occam Design
6.1.6.1 Overview
6.1.6.2 Pipeline Product Portfolio
6.1.6.3 Top Competitors
6.1.6.4 Target Customers
6.1.6.5 Key Personnel
6.1.6.6 Analyst View
6.1.7 Infuseon Therapeutics Inc
6.1.7.1 Overview
6.1.7.2 Pipeline Product Portfolio
6.1.7.3 Top Competitors
6.1.7.4 Target Customers
6.1.7.5 Key Personnel
6.1.7.6 Analyst View
6.1.8 Neurochase
6.1.8.1 Overview
6.1.8.2 Pipeline Product Portfolio
6.1.8.3 Top Competitors
6.1.8.4 Target Customers
6.1.8.5 Key Personnel
6.1.8.6 Analyst View
6.1.9 GE HealthCare
6.1.9.1 Overview
6.1.9.2 Top Products/Product Portfolio
6.1.9.3 Top Competitors
6.1.9.4 Target Customers
6.1.9.5 Key Personnel
6.1.9.6 Analyst View
6.1.9.7 GE HealthCare, Revenue ($Million), 2022-2024
6.1.10 Koninklijke Philips N.V.
6.1.10.1 Overview
6.1.10.2 Top Products/Product Portfolio
6.1.10.3 Top Competitors
6.1.10.4 Target Customers
6.1.10.5 Key Personnel
6.1.10.6 Analyst View
7 RESEARCH METHODOLOGY
7.1 Data Sources
7.1.1 Primary Data Sources
7.1.2 Secondary Data Sources
7.1.3 Data Triangulation
7.2 Market Estimation and Forecast
Scope and Definition
1 MARKET: INDUSTRY OUTLOOK
1.1 Competitive Landscape
1.2 Industry Outlook
1.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
1.2.2 Market Trends
1.2.2.1 Integration of Imaging with Targeted Drug Delivery
1.2.3 Advancements in Image-Guided Drug Delivery
1.2.4 Future Direction and Emerging Technologies in Image-Guided Drug Delivery
1.3 Market Dynamics
1.3.1 Impact Analysis
1.3.2 Market Driver
1.3.2.1 Increased Demand for Personalized Medicine
1.3.2.2 Rising Prevalence of Chronic Diseases
1.3.2.3 Technological Advancements in Image-Guided Drug Delivery
1.3.3 Market Restraint
1.3.3.1 High Acquisition Cost of the Instruments
1.3.4 Market Opportunity
1.3.4.1 Integration of Artificial Intelligence in Image-Guided Drug Delivery
2 TECHNOLOGY
2.1 Overview
2.2 Drug Delivery Systems
2.3 Image-Guided Platforms
3 APPLICATION
3.1 Overview
3.2 Oncology
3.3 Neurology
3.4 Others
4 END USER
4.1 Overview
4.2 Hospitals
4.3 Research Institutes and Universities
4.4 Pharmaceutical and Biotechnology Companies
4.5 Contract Research Organizations (CROs)
5 REGION
5.1 Regional Summary
5.2 North America
5.2.1 Regional Overview
5.2.2 Driving Factors for Market Growth
5.2.3 Factors Challenging the Market
5.2.4 By Technology Type
5.2.5 By Application
5.2.6 By End User
5.2.7 By Country
5.2.7.1 U.S.
5.2.8 By Technology Type
5.2.9 By Application
5.2.10 By End User
5.2.10.1 Canada
5.2.11 By Technology Type
5.2.12 By Application
5.2.13 By End User
5.3 Europe
5.3.1 Regional Overview
5.3.2 Driving Factors for Market Growth
5.3.3 Factors Challenging the Market
5.3.4 By Technology Type
5.3.5 By Application
5.3.6 By End User
5.3.7 By Country
5.3.7.1 U.K.
5.3.8 By Technology Type
5.3.9 By Application
5.3.10 By End User
5.3.10.1 Germany
5.3.11 By Technology Type
5.3.12 By Application
5.3.13 By End User
5.3.13.1 France
5.3.14 By Technology Type
5.3.15 By Application
5.3.16 By End User
5.3.16.1 Italy
5.3.17 By Technology Type
5.3.18 By Application
5.3.19 By End User
5.3.19.1 Spain
5.3.20 By Technology Type
5.3.21 By Application
5.3.22 By End User
5.3.22.1 Rest-of-Europe
5.3.23 By Technology Type
5.3.24 By Application
5.3.25 By End User
5.4 Asia-Pacific
5.4.1 Regional Overview
5.4.2 Driving Factors for Market Growth
5.4.3 Factors Challenging the Market
5.4.4 By Technology Type
5.4.5 By Application
5.4.6 By End User
5.4.7 By Country
5.4.7.1 Japan
5.4.8 By Technology Type
5.4.9 By Application
5.4.10 By End User
5.4.10.1 China
5.4.11 By Technology Type
5.4.12 By Application
5.4.13 By End User
5.4.13.1 India
5.4.14 By Technology Type
5.4.15 By Application
5.4.16 By End User
5.4.16.1 Australia
5.4.17 By Technology Type
5.4.18 By Application
5.4.19 By End User
5.4.19.1 South Korea
5.4.20 By Technology Type
5.4.21 By Application
5.4.22 By End User
5.4.22.1 Rest-of-Asia-Pacific
5.4.23 By Technology Type
5.4.24 By Application
5.4.25 By End User
5.5 Rest-of-the-World
5.5.1 Regional Overview
5.5.2 Driving Factors for Market Growth
5.5.3 Factors Challenging the Market
5.5.4 By Technology Type
5.5.5 By Application
5.5.6 By End User
5.5.7 Latin America
5.5.7.1 Regional Overview
5.5.7.2 Driving Factors for Market Growth
5.5.7.3 Factors Challenging the Market
5.5.8 Middle East and Africa
5.5.8.1 Regional Overview
5.5.8.2 Driving Factors for Market Growth
5.5.8.3 Factors Challenging the Market
5.5.9 Rest-of-the-World Country Overview
6 MARKETS - COMPANY PROFILES
6.1 Company Profiles
6.1.1 ClearPoint Neuro, Inc.
6.1.1.1 Overview
6.1.1.2 Top Products/Product Portfolio
6.1.1.3 Top Competitors
6.1.1.4 Target Customers
6.1.1.5 Key Personnel
6.1.1.6 Analyst View
6.1.1.7 ClearPoint Neuro, Inc., Revenue ($Thousand), 2022-2024
6.1.2 AiM Medical Robotics
6.1.2.1 Overview
6.1.2.2 Pipeline Product Portfolio
6.1.2.3 Top Competitors
6.1.2.4 Target Customers
6.1.2.5 Key Personnel
6.1.2.6 Analyst View
6.1.3 TriSalus Life Sciences
6.1.3.1 Overview
6.1.3.2 Top Products/Product Portfolio
6.1.3.3 Top Competitors
6.1.3.4 Target Customers
6.1.3.5 Key Personnel
6.1.3.6 Analyst View
6.1.3.7 TriSalus Life Sciences, Revenue ($Thousand), 2022-2024
6.1.4 RenovoRx Inc.
6.1.4.1 Overview
6.1.4.2 Top Products/Product Portfolio
6.1.4.3 Top Competitors
6.1.4.4 Target Customers
6.1.4.5 Key Personnel
6.1.4.6 Analyst View
6.1.4.7 RenovoRx Inc., Revenue ($Thousand), 2022-2024
6.1.5 Renishaw plc.
6.1.5.1 Overview
6.1.5.2 Pipeline Product Portfolio
6.1.5.3 Top Competitors
6.1.5.4 Target Customers
6.1.5.5 Key Personnel
6.1.5.6 Analyst View
6.1.5.7 Renishaw plc., Revenue ($Million), 2022-2024
6.1.6 Occam Design
6.1.6.1 Overview
6.1.6.2 Pipeline Product Portfolio
6.1.6.3 Top Competitors
6.1.6.4 Target Customers
6.1.6.5 Key Personnel
6.1.6.6 Analyst View
6.1.7 Infuseon Therapeutics Inc
6.1.7.1 Overview
6.1.7.2 Pipeline Product Portfolio
6.1.7.3 Top Competitors
6.1.7.4 Target Customers
6.1.7.5 Key Personnel
6.1.7.6 Analyst View
6.1.8 Neurochase
6.1.8.1 Overview
6.1.8.2 Pipeline Product Portfolio
6.1.8.3 Top Competitors
6.1.8.4 Target Customers
6.1.8.5 Key Personnel
6.1.8.6 Analyst View
6.1.9 GE HealthCare
6.1.9.1 Overview
6.1.9.2 Top Products/Product Portfolio
6.1.9.3 Top Competitors
6.1.9.4 Target Customers
6.1.9.5 Key Personnel
6.1.9.6 Analyst View
6.1.9.7 GE HealthCare, Revenue ($Million), 2022-2024
6.1.10 Koninklijke Philips N.V.
6.1.10.1 Overview
6.1.10.2 Top Products/Product Portfolio
6.1.10.3 Top Competitors
6.1.10.4 Target Customers
6.1.10.5 Key Personnel
6.1.10.6 Analyst View
7 RESEARCH METHODOLOGY
7.1 Data Sources
7.1.1 Primary Data Sources
7.1.2 Secondary Data Sources
7.1.3 Data Triangulation
7.2 Market Estimation and Forecast
LIST OF FIGURES
Figure 1: Global Image-Guided Drug Delivery Market (by Scenario), $Million, 2024, 2030, and 2035
Figure 2: Global Image-Guided Drug Delivery Market, 2024 and 2035
Figure 3: Top 9 Countries, Global Image-Guided Drug Delivery Market, $Million, 2024
Figure 4: Global Image-Guided Drug Delivery Market Snapshot
Figure 5: Global Image-Guided Drug Delivery Market, $Million, 2024 and 2035
Figure 6: Global Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
Figure 7: Global Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
Figure 8: Global Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
Figure 9: Image-Guided Drug Delivery Market Segmentation
Figure 10: Global Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
Figure 11: Global Image-Guided Drug Delivery Market (Drug Delivery Systems), $Million, 2024-2035
Figure 12: Global Image-Guided Drug Delivery Market (Image-Guided Platforms), $Million, 2024-2035
Figure 13: Global Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
Figure 14: Global Image-Guided Drug Delivery Market (Oncology), $Million, 2024-2035
Figure 15: Global Image-Guided Drug Delivery Market (Neurology), $Million, 2024-2035
Figure 16: Global Image-Guided Drug Delivery Market (Others), $Million, 2024-2035
Figure 17: Global Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
Figure 18: Global Image-Guided Drug Delivery Market (Hospitals), $Million, 2024-2035
Figure 19: Global Image-Guided Drug Delivery Market (Research Institutes and Universities), $Million, 2024-2035
Figure 20: Global Image-Guided Drug Delivery Market (Pharmaceutical and Biotechnology Companies), $Million, 2024-2035
Figure 21: Global Image-Guided Drug Delivery Market (Contract Research Organizations (CROs), $Million, 2024-2035
Figure 22: U.S. Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 23: Canada Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 24: U.K. Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 25: Germany Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 26: France Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 27: Italy Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 28: Spain Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 29: Rest-of-Europe Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 30: Japan Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 31: China Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 32: India Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 33: Australia Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 34: South Korea Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 35: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 36: Data Triangulation
Figure 37: Top-Down and Bottom-Up Approach
Figure 38: Assumptions and Limitations
Figure 1: Global Image-Guided Drug Delivery Market (by Scenario), $Million, 2024, 2030, and 2035
Figure 2: Global Image-Guided Drug Delivery Market, 2024 and 2035
Figure 3: Top 9 Countries, Global Image-Guided Drug Delivery Market, $Million, 2024
Figure 4: Global Image-Guided Drug Delivery Market Snapshot
Figure 5: Global Image-Guided Drug Delivery Market, $Million, 2024 and 2035
Figure 6: Global Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
Figure 7: Global Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
Figure 8: Global Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
Figure 9: Image-Guided Drug Delivery Market Segmentation
Figure 10: Global Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
Figure 11: Global Image-Guided Drug Delivery Market (Drug Delivery Systems), $Million, 2024-2035
Figure 12: Global Image-Guided Drug Delivery Market (Image-Guided Platforms), $Million, 2024-2035
Figure 13: Global Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
Figure 14: Global Image-Guided Drug Delivery Market (Oncology), $Million, 2024-2035
Figure 15: Global Image-Guided Drug Delivery Market (Neurology), $Million, 2024-2035
Figure 16: Global Image-Guided Drug Delivery Market (Others), $Million, 2024-2035
Figure 17: Global Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
Figure 18: Global Image-Guided Drug Delivery Market (Hospitals), $Million, 2024-2035
Figure 19: Global Image-Guided Drug Delivery Market (Research Institutes and Universities), $Million, 2024-2035
Figure 20: Global Image-Guided Drug Delivery Market (Pharmaceutical and Biotechnology Companies), $Million, 2024-2035
Figure 21: Global Image-Guided Drug Delivery Market (Contract Research Organizations (CROs), $Million, 2024-2035
Figure 22: U.S. Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 23: Canada Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 24: U.K. Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 25: Germany Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 26: France Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 27: Italy Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 28: Spain Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 29: Rest-of-Europe Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 30: Japan Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 31: China Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 32: India Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 33: Australia Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 34: South Korea Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 35: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market, $Million, 2024-2035
Figure 36: Data Triangulation
Figure 37: Top-Down and Bottom-Up Approach
Figure 38: Assumptions and Limitations
LIST OF TABLES
Table 1: Market Snapshot
Table 2: Global Image-Guided Drug Delivery Market (by Region), $Million, 2024-2035
Table 3: North America Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 4: North America Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 5: North America Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 6: U.S. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 7: U.S. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 8: U.S. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 9: Canada Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 10: Canada Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 11: Canada Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 12: Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 13: Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 14: Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 15: U.K. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 16: U.K. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 17: U.K. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 18: Germany Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 19: Germany Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 20: Germany Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 21: France Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 22: France Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 23: France Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 24: Italy Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 25: Italy Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 26: Italy Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 27: Spain Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 28: Spain Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 29: Spain Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 30: Rest-of-Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 31: Rest-of-Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 32: Rest-of-Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 33: Asia-Pacific Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 34: Asia-Pacific Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 35: Asia-Pacific Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 36: Japan Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 37: Japan Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 38: Japan Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 39: China Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 40: China Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 41: China Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 42: India Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 43: India Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 44: India Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 45: Australia Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 46: Australia Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 47: Australia Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 48: South Korea Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 49: South Korea Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 50: South Korea Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 51: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 52: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 53: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 54: Rest-of-the-World Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 55: Rest-of-the-World Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 56: Rest-of-the-World Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 1: Market Snapshot
Table 2: Global Image-Guided Drug Delivery Market (by Region), $Million, 2024-2035
Table 3: North America Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 4: North America Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 5: North America Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 6: U.S. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 7: U.S. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 8: U.S. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 9: Canada Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 10: Canada Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 11: Canada Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 12: Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 13: Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 14: Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 15: U.K. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 16: U.K. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 17: U.K. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 18: Germany Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 19: Germany Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 20: Germany Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 21: France Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 22: France Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 23: France Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 24: Italy Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 25: Italy Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 26: Italy Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 27: Spain Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 28: Spain Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 29: Spain Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 30: Rest-of-Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 31: Rest-of-Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 32: Rest-of-Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 33: Asia-Pacific Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 34: Asia-Pacific Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 35: Asia-Pacific Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 36: Japan Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 37: Japan Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 38: Japan Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 39: China Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 40: China Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 41: China Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 42: India Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 43: India Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 44: India Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 45: Australia Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 46: Australia Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 47: Australia Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 48: South Korea Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 49: South Korea Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 50: South Korea Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 51: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 52: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 53: Rest-of-Asia-Pacific Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
Table 54: Rest-of-the-World Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
Table 55: Rest-of-the-World Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
Table 56: Rest-of-the-World Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
